(NASDAQ: CRMD) Cormedix's forecast annual revenue growth rate of 57.11% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 58.44%, and while it is forecast to beat the US market's average forecast revenue growth rate of 9.76%.
Cormedix's revenue in 2025 is $82,553,827.On average, 2 Wall Street analysts forecast CRMD's revenue for 2025 to be $10,564,368,886, with the lowest CRMD revenue forecast at $9,400,497,737, and the highest CRMD revenue forecast at $11,728,240,034. On average, 2 Wall Street analysts forecast CRMD's revenue for 2026 to be $15,708,530,148, with the lowest CRMD revenue forecast at $14,528,720,204, and the highest CRMD revenue forecast at $16,888,340,091.
In 2027, CRMD is forecast to generate $22,056,579,107 in revenue, with the lowest revenue forecast at $22,056,579,107 and the highest revenue forecast at $22,056,579,107.